Genmab announced Thursday that a US District Court entered a final judgment in favour of GlaxoSmithKline in a patent infringement case filed by Roche's Genentech unit and Biogen Idec related to Arzerra (ofatumumab).
Genentech and Biogen Idec filed the suit last year, alleging that Arzerra infringed a certain patent covering methods of treating chronic lymphocytic leukaemia (CLL) with anti-CD20 antibodies. GlaxoSmithKline denied infringement, claiming that the patent was invalid and unenforceable.
In making its decision, Genmab noted that the court defined certain terms of the patent claims, with Genentech and Biogen Idec conceding to a judgment in favour of GlaxoSmithKline. Genentech and Biogen Idec have the right to appeal the decision.
Genmab's anti-CD20 antibody Arzerra is partnered with GlaxoSmithKline and sold in the US and Europe for the treatment of fludarabine and alemtuzumab refractory CLL.
To read more Top Story articles, click here.